Keywords: New Zealand, PHARMAC, Roche, Avstin, MabThera, Valcyte, Hypnovl

New Zealand's PHARMAC decisions on Roche products

Article | 11 October 2012

Print This

PHARMAC, the pharmaceutical management agency in New Zealand, has made decisions on the proposal for various products from Swiss drug ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in